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Abstract Cutaneous allodynia (CA) has been described
in migraine and has been related to treatment failure. There
are little data about the incidence of CA in other primary
headache syndromes such as cluster headache (CH). The
objectives of this study are to evaluate the prevalence of
dynamic mechanical (brush) allodynia (BA) in CH patients
attending a tertiary headache clinic, and to assess its rela-
tion to disease characteristics. Adult patients with episodic
or chronic CH were recruited. We obtained demographic
data and data on disease characteristics through a struc-
tured questionnaire, and tested the patients for brush allo-
dynia BA by applying a 4 9 4 gauze pad over the V1, C2/
C3 and C8 skin areas bilaterally. The prevalence of allo-
dynia in the entire study population and in the different
sub-groups was calculated. We also examined the associ-
ation between CA and demographic parameters, and its
association with disease characteristics. Forty-one patients
were recruited (22 men, 19 women; mean age 44.9 years).
Twenty-two had chronic CH (CCH) and 19 had episodic
CH (ECH). Mean disease duration was 14.1 years (12.3 the
CCH group and 15.7 in the ECH group). Overall, 20 (49%)
patients were allodynic. There was no statistically signifi-
cant association between the presence of allodynia and age,
gender, diagnosis (episodic vs. chronic CH), disease
duration or disease severity. In conclusion, BA was com-
mon in this CH patient sample. The therapeutic
implications of the presence of BA in CH need to be further
studied.
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Introduction
Cutaneous allodynia (CA) is the experience of pain when a
non-noxious stimulus is applied to normal skin [1]. Studies
have shown that up to 80% of patients with episodic
migraine experience allodynia during an acute attack [1, 2].
Some of these studies used a questionnaire to identify
allodynic migraine patients [3, 4], while in others, patients
were tested for mechanical or thermal allodynia using
quantitative sensory testing (QST) or other methods [5, 6].
Allodynia is also common in patients with chronic
migraine, [7] and these patients may exhibit allodynia even
when they do not experience acute headache exacerbations
[8]. Allodynia in migraine is the clinical correlate of central
sensitization of neurons in the trigeminal nucleus caudalis
[9]. The identification of allodynia in migraine may have
therapeutic implications [10], although this notion has been
debated [11].
Cluster headache (CH) is a severe primary headache
syndrome. The pathogenesis of CH is not completely
understood but neuroimaging data suggest involvement of
the hypothalamus [12]. The trigeminovascular and auto-
nomic nervous systems are also thought to be involved
[13]. In a previous study, we found that 40% of our CH
patients experienced CA, and that median disease duration
was longer in allodynic, as compared with non-allodynic,
patients [14]. Another recent study, however, failed to
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confirm these results [15]. CA can occur during acute CH
attacks [16] and successful acute CH treatment with oxy-
gen may reduce CA associated with an attack [17].
Since the current data on the occurrence of allodynia in
CH are inconsistent, we sought to further investigate this
question in a larger number of patients. The goal of this
study was to evaluate the prevalence of dynamic mechan-
ical (brush) allodynia (BA) in CH patients attending a
tertiary headache clinic, and to assess its relation to disease
characteristics. We hypothesized that BA will be common
in our CH patients.
Methods
Study participants
This study was approved by the Institutional Review Board
of Thomas Jefferson University. All subjects signed an
informed consent form prior to enrollment. We studied
adult (age [ 18 years) patients with episodic CH (ECH) or
chronic CH (CCH), as defined by ICHD-2 criteria [18],
recruited from our out-patient clinic.
Exclusion criteria were as follows: abnormal sensory
symptoms or findings on neurological examination, per-
formed by one of the authors, other than allodynia (e.g.,
hypoesthesia, numbness, paresthesias); any neurological
disease that could affect skin sensation, such as multiple
sclerosis, stroke or peripheral neuropathy; co-existent
migraine; treatment with peripheral nerve block within the
4-week period prior to enrollment; treatment with Botu-
linum neurotoxin within the 4-month period prior to
enrollment; and the use of any acute pain medication, in the
24-h period before allodynia testing. Subjects were allowed
to be on headache preventive medications during the study
period. However, those who were using opioid drugs on a
daily basis were excluded. Subjects who had participated in
our previous pilot study [14] were allowed to participate in
the current study.
We obtained demographic data and data on disease
characteristics through a structured oral questionnaire. We
determined the diagnosis through the results of a 10-item
questionnaire that was based on ICHD-2 criteria [18] and
on previous studies [19]. We used these data to diagnose
subjects with either ECH or CCH, and to determine disease
severity and duration. We recorded all acute and preventive
medications used by the patients for headache or for other
conditions.
For each patient, we also documented the following
clinical parameters: headache severity, as measured on a
5-point verbal scale (range 0–4); the proportion of time
spent with headache, i.e., the ratio between the time a
patient had head pain and the time he/she did not, where 0
means no headache at all and 1 means constant headache
(range 0-1); and disease-severity index (defined as the
proportion of time spent with headache 9 mean headache
severity) (range 0–4).
Allodynia testing
Allodynia testing was done when the patients were not
experiencing an acute CH attack. We tested for BA by
folding a 4 9 4 in. gauze pad in half and brushing it lightly
over the patient’s skin ten times at a rate of 2 s-1, as we
described before [14]. The tested skin areas were the
forehead (V1), posterior neck (C2/C3) and inner forearm
(C8). For each skin area, allodynia was tested sequentially
on both sides. We measured allodynia for the tenth stim-
ulus at each skin area using a 100 mm visual analog scale
(VAS). We have previously shown that healthy controls
show a score of 0 when tested for allodynia using this
method [8]. Therefore, a VAS score greater than 0 was
considered a positive result in this study. Using this method
in migraine patients, we have previously found an allo-
dynia prevalence of 86% during acute attacks [5], a result
similar to that obtained in a study that used QST for the
same purpose [1].
The prevalence of BA in the entire study population and
in the different sub-groups was calculated.
Statistical analysis
Fisher’s exact test was used to compare nominal variables
between groups. The Wilcoxon rank-sum test was used to
compare interval and ordinal variables between groups. A
P value of \0.05 was considered to reflect statistical
significance.
Results
We included 41 subjects in this study [22 (54%) men, 19
(46%) women; mean age 44.9 ± 10.5 years]. Twenty-two
subjects (54%) had ECH and 19 (46%) had CCH. Of the
ECH patients, 3 (14%) were examined outside their
headache cycle. Mean disease duration was 14.1 ±
12 years (ECH 15.7 ± 13.8 years, CCH 12.3 ± 9.6 years.)
Disease severity index was significantly higher in subjects
with CCH, compared with those who had ECH
(0.45 ± 0.51 vs. 0.11 ± 0.11, P \ 0.001). The majority of
patients (31/41, 76%) were taking preventive prescription
medications at the time of the study, including 15/19 (79%)
of CCH patients. The most commonly used preventives
were verapamil (24/41, 59%), topiramate (9/41, 22%) and
divalproex sodium (6/41, 15%).
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Twenty (49%) subjects experienced BA (Table 1).
There was no significant difference between allodynic and
non-allodynic subjects with regard to age, gender or
headache severity. BA was more common in subjects with
ECH as compared with those who had CCH, but this
between-group difference was not statistically significant
(55 vs. 42%, P = 0.54). Median disease duration was
10 years in the non-allodynic group and 11 years in the
allodynic group (P = 0.83).
The most common site of BA was V1 (18/41, 44%),
followed by C2/3 (11/41, 27%) and C8 (8/41, 20%). Only
one allodynic subject had BA at a cervical dermatome but
not at V1 (Table 2).
Discussion
This is the largest study to date that examined the preva-
lence of allodynia in CH. We found that CA was common
in our CH sample. This study suggests that allodynia and
central sensitization may be important in the pathophysi-
ology of CH. These data also suggest that the mechanisms
of allodynia in migraine and CH may differ. This
hypothesis and the specific mechanisms of allodynia in CH
need to be further studied.
Allodynia is likely a result of altered processing of
sensory input in the trigeminal nucleus caudalis and may
explain why acute migraine treatment is more effective
early in an attack (when pain is mild). It has been debated
whether the presence of CA modulates the efficacy of
triptans in acute migraine treatment [20], as medications
such as dihydroergotamine may reverse central sensitiza-
tion [21]. Clinical features and neuroimaging studies sug-
gest that the hypothalamus is more important in the
pathophysiology of CH, than in migraine. Subcutaneous
sumatriptan is overwhelmingly effective for most CH
patients, despite the fact that they usually do not have the
chance to treat the attack when head pain is mild. These
observations suggest that the clinical implications of allo-
dynia in these two primary headache disorders may differ.
High-flow oxygen is also generally effective in CH, and
hyperoxia can affect the extravasation of plasma proteins
and decrease levels of calcitonin gene-related peptide [22].
In contrast to our results, Ladda et al. [15] found
increased sensory thresholds (i.e., decreased skin sensitiv-
ity) in CH subjects. Using QST, they examined their sub-
jects for allodynia at the V2, but not at the V1, skin area.
Our study suggests that allodynia in CH is more common at
V1. The pain of CH is most commonly located at the
periorbital, frontal and temporal areas. Therefore, by not
examining for allodynia at the V1 area, Ladda et al. may
have underestimated the occurrence of CA in their CH
subjects.
Subjects with CCH in this study had increased disease
severity, as demonstrated by higher disease severity index,
compared with those with ECH. However, CCH subjects
were not more likely to have allodynia than ECH subjects.
There was no association between allodynia and disease
duration in this study. In contrast, in a study of migraine
patients, the presence of allodynia was associated with
longer disease duration [7] Further studies should investi-
gate the possible association of allodynia with various
characteristics of CH, such as disease severity, response to
acute treatment (oxygen, sumatriptan), presence of
migraine features during attacks, and the serum levels
of biomarkers (e.g., brain-derived neurotrophic factor [23]
or calcitonin gene-related peptide).
Women represented nearly half of our study sample,
unlike the typical gender distribution in CH patients in the
general population. This probably reflects a selection bias
of a clinic-based study.
Our study is limited by the fact that the majority of
subjects were using preventive medications. Since some
headache preventive drugs (e.g., gabapentin) may reduce
allodynia [24], this may have confounded our results. The
different patterns of use of preventive medication between
patients with CCH and ECH may have influenced the
results of this study. Although no subject in this study was
using opioid maintenance therapy for CH or other
conditions, we did not exclude patients with recent opioid
use. Since, opioid-induced hyperalgesia is increasingly
Table 1 Prevalence of brush
allodynia by diagnosis
Episodic
CH (n = 22)
Chronic




Allodynic 12 (55%) 8 (42%) 20 (49%) 0.54
Non-allodynic 10 (45%) 11 (58%) 21 (51%)
Table 2 No. (%) of subjects with allodynia at the different skin areas








V1 18 90 44
C2/3 11 55 27
C8 8 40 20
a Numbers in columns do not add up to 100% as subjects may have
had allodynia at more than one site
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recognized as a common cause of allodynia [25], this may
have affected our results.
In summary, brush allodynia was common in our sample
of CH patients. The mechanistic and therapeutic implica-
tions of this observation need to be evaluated in future
studies. In addition, it will be important to evaluate the
possible effect of preventive medications on the prevalence
of allodynia in CH, and the possible association between
allodynia and response to treatment in this disease.
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